1. To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012;12:204.
2. Asher MI, Garcia-Marcos L, Pearce NE, Strachan DP. Trends in worldwide asthma prevalence. Eur Respir J. 2020;56(6).
3. Forno E, Gogna M, Cepeda A, Yanez A, Sole D, Cooper P, et al. Asthma in Latin America. Thorax. 2015;70(9):898-905.
4. Yaghoubi M, Adibi A, Safari A, FitzGerald JM, Sadatsafavi M. The Projected Economic and Health Burden of Uncontrolled Asthma in the United States. Am J Respir Crit Care Med. 2019;200(9):1102-12.
5. Hekking PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896-902.
6. Enilari O, Sinha S. The Global Impact of Asthma in Adult Populations. Ann Glob Health. 2019;85(1).
7. Ojeda P, Sanz de Burgoa V, Coste Asma S. Costs associated with workdays lost and utilization of health care resources because of asthma in daily clinical practice in Spain. J Investig Allergol Clin Immunol. 2013;23(4):234-41.
8. Asthma GIf. Global Strategy for Ashtma Management and Prevention 2021 [06/05/2021]. Available from: https://ginasthma.org/.
9. Kerstjens HA, Moroni-Zentgraf P, Tashkin DP, Dahl R, Paggiaro P, Vandewalker M, et al. Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status. Respir Med. 2016;117:198-206.
10. Meng JF, Li H, Luo MJ, Li HB. Efficacy of tiotropium in treating patients with moderate-to-severe asthma: A meta-analysis and systematic review based on 14 randomized controlled trials. Medicine (Baltimore). 2019;98(33):e16637.
11. Kew KM, Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst Rev. 2016(1):CD011721.
12. Hong SH, Cho JY, Kim TB, Lee EK, Kwon SH, Shin JY. Cost-Effectiveness of Tiotropium in Elderly Patients with Severe Asthma Using Real-World Data. J Allergy Clin Immunol Pract. 2020.
13. Willson J, Bateman ED, Pavord I, Lloyd A, Krivasi T, Esser D. Cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting beta-agonists. Appl Health Econ Health Policy. 2014;12(4):447-59.
14. Einarson TR, Bereza BG, Nielsen TA, Hemels ME. Utilities for asthma and COPD according to category of severity: a comprehensive literature review. J Med Econ. 2015;18(7):550-63.
15. Lloyd A, Price D, Brown R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J. 2007;16(1):22-7.
16. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Value Health. 2013;16(2):e1-5.
17. (DANE) DNdE. Archivo nacional de datos 2019 [Available from: https://sitios.dane.gov.co/anda-index/. .
18. Ismaila A, Corriveau D, Vaillancourt J, Parsons D, Dalal A, Su Z, et al. Impact of adherence to treatment with tiotropium and fluticasone propionate/salmeterol in chronic obstructive pulmonary diseases patients. Curr Med Res Opin. 2014;30(7):1427-36.
19. Florez-Tanus A, Parra D, Zakzuk J, Caraballo L, Alvis-Guzman N. Health care costs and resource utilization for different asthma severity stages in Colombia: a claims data analysis. World Allergy Organ J. 2018;11(1):26.
20. Jacob C, Haas JS, Bechtel B, Kardos P, Braun S. Assessing asthma severity based on claims data: a systematic review. Eur J Health Econ. 2017;18(2):227-41.
21. Neffen H, Fritscher C, Schacht FC, Levy G, Chiarella P, Soriano JB, et al. Asthma control in Latin America: the Asthma Insights and Reality in Latin America (AIRLA) survey. Rev Panam Salud Publica. 2005;17(3):191-7.
22. Zafari Z, Sadatsafavi M, Mark FitzGerald J, Canadian Respiratory Research N. Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US. Cost Eff Resour Alloc. 2018;16:3.
23. Salud IdETe. Manual metodológico para la elaboración de evaluaciones de efectividad, seguridad y validez diagnóstica de tecnologías en salud. Bogota DC2014 [Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/INEC/IETS/manual-metodologico-elaboracion-de-evaluaciones-de-efectividad.pdf